Immunologic Research

, Volume 47, Issue 1, pp 65–77

High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation

Article

DOI: 10.1007/s12026-009-8139-0

Cite this article as:
Luznik, L. & Fuchs, E.J. Immunol Res (2010) 47: 65. doi:10.1007/s12026-009-8139-0

Abstract

Graft-versus-host disease, or GVHD, is a major complication of allogeneic hematopoietic stem cell transplantation (alloHSCT) for the treatment of hematologic malignancies. Here, we describe a novel method for preventing GVHD after alloHSCT using high-dose, post-transplantation cyclophosphamide (Cy). Post-transplantation Cy promotes tolerance in alloreactive host and donor T cells, leading to suppression of both graft rejection and GVHD after alloHSCT. High-dose, post-transplantation Cy facilitates partially HLA-mismatched HSCT without severe GVHD and is effective as sole prophylaxis of GVHD after HLA-matched alloHSCT. By reducing the morbidity and mortality of alloHSCT, post-transplantation Cy may expand the applications of this therapy to the treatment of autoimmune diseases and non-malignant hematologic disorders such as sickle cell disease.

Keywords

Bone marrow transplantationGraft-versus-host diseaseGraft-versus-leukemia effectCyclophosphamideHuman leukocyte antigensT lymphocytes

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimoreUSA